Core Viewpoint - ORIC Pharmaceuticals is focused on overcoming resistance in cancer, with a mission to develop innovative therapies for oncology patients [3]. Company Overview - ORIC has assembled a team of experienced drug hunters and developers who have previously worked at leading oncology companies, contributing to the development of successful and commercialized products [3]. Pipeline Assets - The company has two late-stage pipeline assets: rinzimetostat, targeting prostate cancer, and enozertinib, aimed at lung cancer [4]. - Significant data on both drugs has been presented in previous years, particularly in 2025, with more data expected to be shared in the current year [4].